Metabolic syndrome
Conditions
Interventions
Ingestion of placebo capsules for 12 consecutive week
Ingestion of capsules include extract of pericarp of mangosteen and extract of lychee for 12 consecutive weeks
Ingestion of capsules include extr
Sponsors
Total Technological Consultant Co., Ltd.(TTC)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Japanese males and females between the ages of 35 and 65 2. abdominal circumference greater or equal 85cm in males and 90 cm in female on preliminary examination 3. applicable to more than two of three following indexes on preliminary examination; blood pressure greater or equal 130/85 mm Hg, triglycerides greater or equal 150mg/dL or serum high-density lipoprotein cholesterol (HDL-C) less 40 mg/dL, blood glucose greater or equal 110 mg/dL, body weight less100 kg, or body mass index greater or equal 25 kg/m2
Exclusion criteria
Exclusion criteria: 1. having exercise or diets for reducing body weight 2. having the medicines or dietary supplements affecting body fat, serum triglyceride, or lipid metabolism potentially 3. having foods fortified with mangosteen or lychee extracts 4. with severe abnormalities of blood pressure or blood test 5. excessive habitual smoker or alcohol addict or extremely irregular food habits person 6. with severe disease receiving treatment 7. needing emergent treatment to diabetes, hepatopathy, renal or heart disease 8. having possibilities of emerging allergy related to the study 9. with pregnant (including with pregnant in plan), or in the lactation period 10. judged to be inadequate by the questionnaire of lifestyles 11. judged to be inadequate by biochemical assessment in blood on preliminary examination 12. taking part in other clinical trials within a month from the initiation of this clinical trial 13. judged to be inadequate by the doctors responsible for this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visceral fat area, body weight(body mass index), abdominal circumstance, blood pressure, triglyceride, HDL-cholesterol, blood glucose | — |
Secondary
| Measure | Time frame |
|---|---|
| Subcutaneous fat area, total fat area, adiponectin, HMW adiponectin, leptin, adiponectin/ leptin, HMW adiponectin/ total adiponectin, HMW adiponectin/ leptin, questionnaire | — |
Countries
Japan
Contacts
Public ContactMuneaki Iizuka
Total Technological Consultant Co., Ltd.(TTC) Clinical Research Planning Dept.
Outcome results
None listed